The therapy success ranges between a full therapy failure, and the complete remission of the tumor and the biomedical and systemic reasons for this range remain unknown so far, but it appears that the variety of different ALK mutations and variants contribute to the discrepant therapy results, especially as the state-of-the-art Vysis test only detects the ALK translocation, but not the respective partner. Here, ALK is linked to neoplasm.